Date: 2011-06-29
Type of information: Completion of patient enrollment
phase: 3
Announcement: completion of patient enrollment
Company: Merck Serono, a Merck KGaA company (Germany) Newron Pharmaceuticals (Italy)
Product: safinamide
Action
mechanism: Safinamde has a novel dual mechanism of action based on theenhancement ofthe dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of excessive release of glutamate.
Disease: Parkinson's disease
Therapeutic area: Neurodegenerative diseases - CNS diseases
Country:
Trial details:
Latest
news: Merck KGaA and its partner Newron Pharmaceuticals have announced that patient enrollment has been completed in the MOTION study. This randomized, double-blind, placebo-controlled, international phase III pivotal trial is designed to evaluate the efficacy and safety of two dose regimens of safinamide (50 and 100 mg once daily), as add-on therapy to a stable dose of a single dopamine agonist, compared with dopamine agonist monotherapy.
A total of 679 patients with early-stage Parkinson’s disease have been randomized in the study.
